![]() ![]() A clinical trial in South Africa convinced officials there that the AstraZeneca vaccine being tested is substantially less effective against the B.1.351 variant that now dominates there. Scientists are not sure how well the current vaccines will prevent the B.1.1.7 variant first identified in the UK. Nonetheless, there are worries on the horizon. In Israel, where nearly half the population has now been vaccinated, cases are dropping dramatically. There is new data suggesting that the immunizations are effective at reducing severe illness and death from COVID-19. Paul Offit is on that panel and describes what the reviewers are looking for in these vaccine hearings. The agency is considering whether to authorize its use in this pandemic emergency. Now, the FDA Advisory Panel will be reviewing information about the vaccine from Johnson & Johnson. Health departments and healthcare systems have been administering the mRNA vaccines from Moderna and Pfizer/BioNTech for a few months. We talk with two experts on these COVID-19 vaccines and variants of the SARS-CoV-2 virus to get you the information you need. ![]() After a year of COVID-19, the country (and the world) is in a race to get people vaccinated before the new, more transmissible variants of the coronavirus can gain the upper hand. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |